8-K: Current report filing
Published on April 27, 2007
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 24, 2007
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Item 1.01 Entry into a Material Definitive Agreement
------------------------------------------
On April 24, 2007, Access Pharmaceuticals, Inc. ("Access") entered into
an amendment to its 7.0% (Subject to Adjustment) Convertible Promissory
Notes with Oracle Partners LP, Oracle Institutional Partners LP, SAM
Oracle Investments Inc. and Oracle Offshore Ltd. agreeing to extend
the maturity date of the notes to June 12, 2007 from April 28, 2007.
The notes in aggregate total $4,015,000.
On April 26, 2007, Access entered into an amendment to its 7.5%
Convertible Notes with SCO Capital Partners LLC, Beach Capital LLC and
Lake End Capital LLC agreeing to extend the maturity date of the notes
to June 11, 2007 from April 27, 2007. The notes in aggregate
total $6,000,000.
All other terms of the notes remain the same.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Access Pharmaceuticals, Inc.
(Registrant)
By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer
Dated April 26, 2007
3